Of note, an imbalance in PD-L1/PD-1 signaling has been suggested in MS pathogenesis and proposed as a potential target in MS treatment, although the role of soluble PD-L1 is not fully established (30). This evidence concerns the gene CD274 and myeloid sarcoma.